Abhinav Vyas, MD
@vyasabhinav2
Followers
510
Following
2K
Media
34
Statuses
391
Hem-Onc Fellow at @llumedschool @lluhealth | HPM alum @VanderbiltU | Doctor | Travel | Culé. 🇮🇳 🇺🇸| RT ≠ endorsement | #pallonc
Nashville, TN
Joined April 2021
I am going to @LLUMedCenter for my Hem-Onc Fellowship. Beyond grateful and elated to share this news. I am finally going to be a #pallonc trained physician. SoCal -HERE WE GO!! Thank you to everyone that supported me!! #match2024 #hematology #oncology
21
6
138
@PallOncCoP @TamrynGray @vyasabhinav2 @DarcyBurbage @Chaosdyna @jillfeldman4 @FionnualaCrowle @T4Cancer @coffeemommy @IshwariaMD @mondhiry Dr @TamrynGray summarizes the 🗻 of #challenges facing #caregivers who are supporting #HSCT patients and seeing the different (often limited) resources to help these patients. @vyasabhinav2 @DarcyBurbage @Chaosdyna @jillfeldman4 @FionnualaCrowle @T4Cancer @coffeemommy
0
6
7
📆Happening today at 4p EST!📆 Excited to share my experience in #hpm with fellow @AAHPM members for #CancerTxSIG free webinar. Send me a DM or join on @AAHPM connect for a zoom link 💻🔗 #pallonc #supponc
@PallOncCoP
@MazieTsangMD
@DarcyBurbage
@Chaosdyna
@crisbergerot
Calling all @AAHPM members! Will have the honor of sharing #EarlyCareer pearls 🦪 as well as how to connect with #oncology from an #hpm perspective for #CancerTxSIG DM me for a zoom link to this free 💸 #webinar on 11/11/25 4p EST or join us on @AAHPM Connect to learn more!
0
5
13
Today is the day! @RyanNipp is one legend you don't want to miss as he summarizes #ASCOQLTY25 for @PallOncCoP. If you don't have the link, send us a message or get added to the listserv. @DanijelaJakovl9
@RichaThakurMD
@RachelA104
@Dr_Butin
@Mombada1
@DrAlisonW
Join us this Thursday to hear the highlights from #ASCOQLTY25 with ASCO Quality Chair Elect @RyanNipp. DM for the link to the meeting or to be added to our mailing list. @anhbl9 @realbowtiedoc @crisbergerot @FionnualaCrowle @Chaosdyna @fumikochino @CThompson_MD @MazieTsangMD
1
6
8
🚨Real World Case Video ✅PFS 15.81 mo, ✅DoR 22.1 mo, ✅ORR 40% with osimertinib—uncommon EGFR mutations in lung cancer just got a possible game-changer! Dr. Darren Wijaya’s MOASC 2025 video Poster 👉 https://t.co/0AlEsmOxeX
@LLUHealth @ADesaiMD @MOASC_Office @Innov_Medicine
10
5
7
A dream come true: Published in the @NEJM as Senior & Corresponding Author! This milestone belongs to my village: my family, my incredible mentors (Dr George) & leaders, and my friends. This one is for you, Doctor Chacha, watching and celebrating from heaven. 🙏 God is good 😇
29
26
262
So so proud of this stellar team at @StephensonCC!!! Congratulations @Nischistocyte!!🤩🤩🤩 @ResearchOU
@OUCollegeofMed
@OU_internalmed
A dream come true: Published in the @NEJM as Senior & Corresponding Author! This milestone belongs to my village: my family, my incredible mentors (Dr George) & leaders, and my friends. This one is for you, Doctor Chacha, watching and celebrating from heaven. 🙏 God is good 😇
0
2
11
Hey, don’t forget to submit that #GI26 abstract! It’s your time to shine and help shape the future of GI cancer care with your #gicsm study in progress or a late-stage clinical trial. Abstracts are due Sept. 9 at 11:59 p.m. (ET). Learn more: https://t.co/s8i1kjUpcz
1
10
21
🚨 Trial Launch! Excited for my investigator-initiated DISCERN study now LIVE @ONealCancerUAB! ➡️PD-L1- advanced #NSCLC with ctDNA response to understand dual vs single IO + chemo, a pragmatic trial! @IASLC @LungCancerRx @OncBrothers @ClinicalLung
https://t.co/j5ZPiIxG67
5
9
72
A summer 🌞 of firsts. Overjoyed to share my #inaugural editorial with 🥇 peer mentor @MazieTsangMD in @JCOOP_ASCO 🤖⏱️ #Wearable tech is transforming #SuppOnc and how we assess patient fitness 🏋️♀️ Excellent work to @EvaRuizHispan and her colleagues @ravi_b_parikh
Excited to share our JCO paper “Objective Performance Status” (OPS), validated with wearables. We established a 1,200 m/day cutoff stratifies metastatic cancer survival (mOS 3.2/11.2;HR 5.76). Grateful to the team and @VicMorenoGarcia for his mentorship 🔗
1
16
53
Excited for this analysis of #HER2 alterations/overexpression is now out in @OncJournal! 👇 @HemOncFellows @LungCancerRx @OncoAlert @oncodaily
Check out our recent analysis @OncJournal under mentorship of @ADesaiMD of 653 solid tumors evaluating HER2 by IHC, CNV & mutational profiling. 📊 Results: •IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg •CN amplification: 3.1% (75% IHC3+) •Pathogenic ERBB2 mutations: 3.1%
0
6
17
Check out our recent analysis @OncJournal under mentorship of @ADesaiMD of 653 solid tumors evaluating HER2 by IHC, CNV & mutational profiling. 📊 Results: •IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg •CN amplification: 3.1% (75% IHC3+) •Pathogenic ERBB2 mutations: 3.1%
2
6
15
Grateful to be able to contribute to this. @mumairmushtaq @PallOncCoP @realbowtiedoc @ConquerCancerFd @hemeoncfellow @ASH_hematology @aksinghmd @KUMedCenter @LLUMedSchool
Impact of MRD on outcomes after allo-HCT for AML https://t.co/e049HZQUmw
@mshahzadmd @KUcancercenter @mrf_org @USMIRCNEWS @oncodaily @aksinghmd @MediHumdani
0
3
8
New Pub - Continuous IVIG (2 g/kg) with 48-hr platelet infusion may safely overcome refractory alloimmune thrombocytopenia after allo-HSCT, serving as a bridge until platelet engraftment or for urgent high-bleeding-risk situations. https://t.co/AL1fb3LJNh.
0
2
10
Our recent publication explores the role of concurrent IVIG and platelet transfusion in patients with refractory #alloITP undergoing #alloHCT. @mumairmushtaq @NausheenAhmedMD @kashifaminMD @Abdallah81MD @MoffittNews
https://t.co/4Z7auDUytk
0
10
23
August 1 marks #WorldLungCancerDay — a time to reflect, raise awareness, and recommit to changing the future of lung cancer. We’ve made meaningful progress, but there’s still a long way to go. Each patient, each study, each step forward brings us closer to better outcomes.
2
11
42
Dr. Anthony El-Khoueiry @uscnorris giving an excellent overview regarding combo #IO in #HCC moderated by @GABOUALFA #cancer #cancerresearch. Great meeting chaired by @GIcancerDoc and @EileenMOReilly @AHPBA
1
4
22
@PalliativeMed_j @DanijelaJakovl9 @RichaThakurMD @RachelA104 @Dr_Butin @MOmbada1 @DrAlisonW @MonikaJ95971150 @AnnaLaVigneMD @doctor_nurse7 @langmannga @AdmaneSonal @RajivAgarwalMD @gandhi_shipra @SiennaDurbin @ComeBommier @veladconmigo @chefaleixomd Ongoing #video summaries of the #Top10Tips paper for #hpm on #survonc published in @PalliativeMed_j Presenting Tip 5⃣ #FinTox 💰💸 @fumikochino
@yzafar
@Mombada1
@MonikaJ95971150
@drtulsijose
@bosnjaksupport
@ChandrikhaC
@GretchenMcnally
@aarsh_a_desai
@IshwariaMD
1
7
16
🔹FLAURA2 confirms it: Osimertinib + chemo sets a new OS record (50.0 vs 42.1 mo, HR 0.75). But does this kill sequential strategy? Not necessarily. Post-progression Amivantamab still matters perhaps even more after earlier TKI + chemo pressure. 🔗 https://t.co/yFhPcAWqix
#EGFR
2
8
24
Join the CME/ACPE-accredited 2025 Seattle Cellular Therapy Summit, where leading experts deliver insights on CAR T therapies, lymphoma management, and breakthrough strategies for hematologic malignancies. Register NOW:
1
10
84